Scarica l'app Stockscreener
16.93
0.29%
-0.05
Theravance Biopharma Inc Borsa (TBPH) Ultime notizie
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
Theravance stock down 3% after Zymeworks announces buyout - MSN
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders - AOL.com
Theravance Biopharma Price Target Raised to $17.00/Share From $15.00 by HC Wainwright & Co. - Moomoo
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
TBPHTheravance Biopharma Inc Options - Finviz
If You Invested $1,000 in Theravance Bioph (TBPH) - Stock Titan
Arthur Cox advises on pharmaceutical sector acquisition - ICLG
Theravance Biopharma Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseEarnings Season Review - dars.gov.et
TBPH News | THERAVANCE BIOPHARMA INC (NASDAQ:TBPH) - ChartMill
Zymeworks to pay $17/share for Theravance Biopharma in $929M deal - MSN
Theravance Biopharma Insider Sold Shares Worth $5,791,555, According to a Recent SEC Filing - marketscreener.com
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock - Moomoo
Funds tied to Eli Samaha trim Theravance Biopharma (TBPH) stake in open-market sales - Stock Titan
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
TBPH SEC FilingsTheravance Bioph 10-K, 10-Q, 8-K Forms - Stock Titan
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Zymeworks to Acquire Theravance Biopharma in $929 Million Transaction - Global Legal Chronicle
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
TBPH Downgraded by BTIG -- Rating Changed to Neutral - GuruFocus
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks to Acquire Theravance Biopharma, Inc. - Indovizka.com
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
Zymeworks to buy Theravance Biopharma in $929M deal – a look at what this deal means for TBPH shareholders - MSN
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance Biopharma (TBPH) Downgraded to Hold Following $929M A - GuruFocus
Theravance downgraded at Jones on Zymeworks acquisition - MSN
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareh - GuruFocus
Are IRDM, TBPH, SYNA, TECH Obtaining Fair Deals for their Shareholders? - Finviz
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH) - PR Newswire
TBPH Downgraded by Jones TradingRating Changed to Hold - GuruFocus
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Ther - GuruFocus
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
Zymeworks expands beyond cancer with $929 million Theravance acquisition - WTVB
Fair Price or Fast Exit? Scrutiny Mounts Over Theravance Biopharma Sale - BriefGlance
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
Zymeworks to acquire Theravance Biopharma for $929M - grafa.com
Zymeworks makes bold move with $929m Theravance Biopharma buy - BioXconomy
Ademi LLP Investigates Whether Theravance Biopharma, Inc. Is Obtaining a Fair Price for Public Shareholders - Moomoo
BTIG Downgrades Theravance Biopharma to Neutral From Buy - Moomoo
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionTheravance Biopharma (NASDAQ - Benzinga
Zymeworks’ Theravance buy adds Yupelri to portfolio - The Pharma Letter
Theravance Biopharma to Be Acquired by Zymeworks for $929 Million Plus Contingent Value Rights - Minichart
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - Yahoo Finance
Zymeworks (ZYME) to Acquire Theravance Biopharma (TBPH) for $929M in All-Cash Transaction - Blockonomi
Zymeworks (ZYME) Stock Acquires Theravance Biopharma in $929 Million COPD Deal - CoinCentral
Zymeworks expands into COPD, buying beleaguered Theravance for $929M - FirstWord Pharma
Zymeworks (NASDAQ: ZYME) buys Theravance, adds YUPELRI cash flows with $350M OMERS note - Stock Titan
Zymeworks (ZYME) to Acquire Theravance Biopharma (TBPH) in $929M Deal - GuruFocus
Zymeworks to acquire Theravance Biopharma for $929 million - Investing.com
Zymeworks strikes $929 million deal for Theravance Biopharma - KELO-AM
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):